Mi Kyong Joung

Mi Kyong Joung

Auto-generated profile, based on publicly available information

Mi Kyong Joung

Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
HCHae Suk Cheong
Hae Suk Cheong
CKCheol‐In Kang
Cheol‐In Kang
JLJeong A. Lee
Jeong A. Lee
SMSoo Youn Moon
Soo Youn Moon
MJMi Kyong Joung
Mi Kyong Joung
KPKyong Ran Peck
Kyong Ran Peck
Background. There have been few reports on the causes and treatment outcomes for nosocomial spontaneous bacterial peritonitis (SBP) in patients with

1 January 2016 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
WCWon Suk Choi
Won Suk Choi
CKCheol-In Kang
Cheol-In Kang
YKYonjae Kim
Yonjae Kim
JCJae-Phil Choi
Jae-Phil Choi
JJJoon Sung Joh
Joon Sung Joh
TDThe Korean Society Of Infectious Diseases
The Korean Society Of Infectious Diseases
Choi WS, et al. Infect Chemother. 2016 Jun;48(2):118-126. https://doi.org/10.3947/ic.2016.48.2.118

2 March 2011 in Critical Care
Verified
Journal Article
Open access
PDF file
KJKyong Mi Joung
Kyong Mi Joung
JLJeong-A Lee
Jeong-A Lee
SMSoo-Youn Moon
Soo-Youn Moon
HCHae Suk Cheong
Hae Suk Cheong
EJEun-Jeong Joo
Eun-Jeong Joo
KPKyong Ran Peck
Kyong Ran Peck
Introduction: De-escalation therapy is a strategy currently used for the management of nosocomial pneumonia. In this study, we evaluated clinical outcomes and risk factors related to de-escalation therapy in patients with intensive care unit (ICU)-acquired pneumonia. Methods: This was a retrospective observational cohort study of ICU patients who developed pneumonia more than 48 hours after admission to the ICU at Samsung Medical Center from September 2004 to December 2007. Results: The 137 patients comprised 44 (32.1%) who received de-escalation therapy and 93 in the non-de-escalation group. The de-escalation group showed a lower pneumonia-related mortality rate than the non-de-escalation group by day 14 (2.3% vs. 10.8%, respectively; P = 0.08) and by day 30 (2.3% vs. 14%, respectively; P = 0.03) after the diagnosis of pneumonia. The variables independently associated with ICU-acquired pneumonia-related mortality included the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and the modified Clinical Pulmonary Infection Score (CPIS) after 5 days with pneumonia. The non-de-escalation group had significantly higher APACHE II score and modified CPIS after 5 days with ICU-acquired pneumonia compared to the de-escalation group. Among all patients, 20.4% (28 of 137) had negative cultures for pathogens, and 42.9% (12 of 28) received de-escalation therapy. The latter 12 patients received de-escalation therapy and survived 30 days after the diagnosis of pneumonia. Conclusions: Patients in the de-escalation group showed a significantly lower mortality rate compared to patients in the non-de-escalation group. De-escalation therapy can be safely provided to patients with ICU-acquired pneumonia if they are clinically stable by day 5, even in those whose respiratory specimen cultures yield no specific pathogens.

30 September 2010 in Journal of Infection
Verified
Journal Article
Closed access
MJMi Kyong Joung
Mi Kyong Joung
KKKi Tae Kwon
Ki Tae Kwon
CKCheol-In Kang
Cheol-In Kang
HCHae Suk Cheong
Hae Suk Cheong
JRJi-Young Rhee
Ji-Young Rhee
KPKyong Ran Peck
Kyong Ran Peck

8 October 2010 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
YHYoung Eun Ha
Young Eun Ha
JSJae-Hoon Song
Jae-Hoon Song
WKWon Ki Kang
Won Ki Kang
KPKyong Ran Peck
Kyong Ran Peck
DCDoo Ryeon Chung
Doo Ryeon Chung
KSKyung Mok Shon
Kyung Mok Shon

1 December 2012 in Microbial Drug Resistance
Verified
Journal Article
Closed access
SMSoo-Youn Moon
Soo-Youn Moon
KPKyong Ran Peck
Kyong Ran Peck
HCHyun-Ha Chang
Hyun-Ha Chang
SKShin-Woo Kim
Shin-Woo Kim
SHSang Taek Heo
Sang Taek Heo
JSJae-Hoon Song
Jae-Hoon Song
Background: Tigecycline has broad spectrum antimicrobial activity and is approved for complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired pneumonia. There are few data on clinical experience of tigecycline in hospital-acquired pneumonia (HAP) and Acinetobacter spp. infection. Methods: A retrospective study was performed at eight hospitals in Korea from May 2009 to January 2010. Adult patients treated with tigecycline regardless of their source of infection or pathogens were enrolled. Results: Tigecycline was administered in 108 patients. Pneumonia was the most common infection (43.5%), followed by skin and soft tissue infections (20.4%). Acinetobacter baumannii was isolated from 83 patients (76.9%) accounting for 50.3% of isolated pathogens, showing a resistance rate of 67.5% to carbapenems. Superinfection was identified in 32 patients (29.6%). Pseudomonas aeruginosa was most common microorganism causing superinfection (46.9%). Overall 30-day mortality rate was 52.9%. Thirty-day mortality rate of HAP and Acinetobacter spp. infection was 60.5% and 59.4%, respectively. Conclusion: Tigecycline can be considered as an alternative therapy in patients with HAP or infections caused by Acinetobacter spp., especially extensively drug-resistant A. baumannii .